Document Type
Article
Publication Date
12-8-2025
Abstract
Introduction: Schizophrenia imposes a substantial burden on individuals and society. Long-acting injectable antipsychotics (LAIs) improve adherence and reduce relapse and hospitalization rates compared with oral treatments for schizophrenia, yet LAI use varies globally. The qualitative interview portion of the global Attitudes DriVing regional differences in long-acting injectable ANtipsychotic utilization for schizophrenia among healthcare professionals (HCPs), patients, and CaregivErs (ADVANCE) study explored the patient journey from schizophrenia diagnosis to treatment, treatment goals, and experiences and perspectives on LAIs that may influence their use. Methods: ADVANCE included HCPs, patients, and caregivers from Australia, Canada, China, Germany, Israel, Spain, South Korea, and the United States. Eligible HCPs spent ≥65% of their time providing direct patient care, managed an adult population of whom ≥10% have schizophrenia, and treated patients with second-generation LAIs. Patients with schizophrenia aged ≥18 years and caregivers of individuals living with schizophrenia who had experience with LAIs were eligible. Participants completed a 60-minute, semi-structured telephone interview. Results: Seventeen HCPs, 20 patients, and 19 caregivers completed interviews. HCPs reported that patients often follow a cycle of treatment and relapse, with inpatient care focused on acute symptoms management, while outpatient treatment was more likely to prioritize long-term quality of life. The most common HCP-reported barriers to LAI use were patient aversion to injections, logistical challenges, and patient trauma from prior forced injection. Two distinct treatment/disease management pathways emerged from patient interviews: 1) treatment early in symptom development with strong outpatient support, and 2) severe, acute episodes that required hospitalization. Patients initially treated in an outpatient setting were likely to accept LAIs, while those treated in inpatient settings often feared treatment, felt a lack of control, and were less likely to accept an LAI for long-term care. Caregivers had roles in disease management and focused more on patient quality of life rather than treatment management. Conclusions: Interactions between patients with schizophrenia and psychiatrists or psychiatric nurses vary depending on the care setting, which can influence the acceptance of LAIs. Initial schizophrenia presentation, family support, hospitalizations, trust in HCPs, and logistical challenges may all play a role in patient outcomes and perceptions of LAIs.
Keywords
caregivers, healthcare professionals, long-acting injectable antipsychotics, patients, schizophrenia, setting of care, treatment preference
Language
English
Publication Title
Frontiers in Psychiatry
Rights
© 2025 The Authors. This is an Open Access work distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Franzenburg KR, Hansen R, Suett M, Yaari A, Sergerie M, Peyser Levin A, Kaplan S, Gonzalez A, Sedigh K, Heres S and Sajatovic M (2025) Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study. Front. Psychiatry 16:1645328. doi: 10.3389/fpsyt.2025.1645328
Manuscript Version
Final Publisher Version